Roche Q1 Financial Report Interpretation: Revenue Grows 6% YoY, China Leads International Business Growth

On April 24, Roche announced its financial results for Q1 2025, with group sales increasing by 6% year-on-year (7% in Swiss Francs) at CER, reaching CHF 15.4 billion. This growth was primarily driven by strong demand for innovative drugs and diagnostic solutions, which offset the impact of expiring patents and China’s healthcare pricing reforms.

Core Business Performance Shines, Innovative Products Drive Growth

The pharmaceutical business saw an 8% increase in sales year-on-year (9% in Swiss Francs), reaching CHF 11.9 billion. Key growth drivers include:

• Phesgo (Breast Cancer): Global demand surged, with sales reaching CHF 593 million, a 52% year-on-year increase, with particularly strong performance in the Chinese market.
• Vabysmo (Severe Eye Disease): Sales exceeded CHF 1 billion, a year-on-year increase of 18%, covering all major markets.
• Hemlibra (Hemophilia A) and Xolair (Allergy): Contributed CHF 1.165 billion and CHF 645 million respectively, with year-on-year increases of 11% and 26%.

The diagnostics business remained stable, reaching CHF 3.49 billion. Despite pricing pressures from China’s reforms, demand for immunodiagnostics and pathology solutions offset the negative impact. Sales in the EMEA region grew by 4%, North America grew by 7%, while Asia Pacific declined by 15% due to adjustments in the Chinese market.

R&D Milestones: Approvals for Multiple Therapies, Breakthroughs in Alzheimer's and Obesity Fields

Roche achieved several key developments in Q1:

• Regulatory Approvals:
  • Evrysdi tablets were approved by the US FDA as the first oral tablet for treating spinal muscular atrophy (SMA).
  • Susvimo was approved by the US for diabetic macular edema (DME), becoming the first alternative to frequent eye injections for sustained drug delivery.
  • The EU approved Columvi in combination with chemotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), showing a 41% reduction in the risk of death in phase III trials.
• Clinical Progress: Alzheimer's antibody Trontinemab and new Hemophilia A drug NXT007 entered phase III clinical trials.
• Exclusive Partnership: Roche formed an exclusive collaboration with Zealand Pharma to co-develop amylin analogs and a fixed-dose combination with Roche’s GLP-1 drug CT-388, targeting the global obesity treatment market.
• Technological Breakthrough: Roche launched the revolutionary “Sequencing Expansion” (SBX) technology, reducing whole genome sequencing time from days to hours, which could accelerate precise diagnosis of cancer and neurodegenerative diseases.

Strategic Investments in the US: $5 Billion Investment and Innovation Center Launch

Roche announced plans to invest $50 billion in the US over the next five years to expand its R&D and manufacturing facilities, which is expected to create 12,000 jobs. Meanwhile, the Roche Genentech Boston Innovation Center will be launched in the Harvard Business Research Park, focusing on cardiovascular, metabolic diseases, and AI-driven drug development. Roche currently has over 25,000 employees and 28 R&D and manufacturing facilities in the US.

Regional Market Analysis: China Leads International Growth

The market performance by region is as follows:

• US: Pharmaceutical sales grew by 6%, with Xolair, Phesgo, and Vabysmo being the key drivers.
• Europe: Sales grew by 5%, with Vabysmo and Polivy (blood cancer) showing strong performance.
• Japan: Sales grew by 3%, with significant contributions from Phesgo and flu drug Xofluza (sales increased by 234% year-on-year).
• International (including China): Sales grew by 18%, with China’s sales increasing by 14% year-on-year, benefiting from the demand for Phesgo and Xofluza.

Full-Year Outlook: Maintaining Mid-Single-Digit Growth Target

Roche has confirmed its 2025 full-year outlook: Group sales are expected to grow in the mid-single digits at CER, with core EPS expected to grow in the high single digits, and a plan to increase dividend distribution. CEO Thomas Schinecker said, “Our investments in innovation pipelines, diagnostic technologies, and global infrastructure are continuously translating into performance momentum. As new therapies for Alzheimer's and obesity enter late-stage clinical trials, along with the commercialization of SBX technology, Roche will continue to lead the transformation of the healthcare industry.”

Roche CEO Thomas Schinecker stated, "We have had a strong start this year and have achieved many important milestones. In terms of pipeline progress, Trontinemab for Alzheimer's disease and NXT007 for Hemophilia A are about to enter phase III clinical trials. At the same time, Roche currently has over 25,000 employees, 15 R&D centers, and 13 manufacturing sites. To expand its business in the US, Roche announced plans to invest $50 billion in the pharmaceutical and diagnostics R&D and manufacturing sectors over the next five years."

Pipeline Reductions

It is noteworthy that the quarterly report mentioned Roche has discontinued three pipeline projects, which are:

• TGF-β3 Monoclonal Antibody RG6315: Phase I study for fibrosis treatment.
• Muc1 CAR-T Cell Therapy P-MUC1C-ALLO1: Phase I study for solid tumors treatment.
• TIGIT Monoclonal Antibody Tiragolumab: Phase III study in combination with atezolizumab for the treatment of locally advanced esophageal cancer.